| 防治新冠病毒化学药物专利合作网络演化研究 |
| |
| 引用本文： | 姜 南,李鹏媛,刘 星.防治新冠病毒化学药物专利合作网络演化研究[J].科技管理研究,2021,41(7):140-147. |
| |
| 作者姓名： | 姜 南 李鹏媛 刘 星 |
| |
| 作者单位： | 同济大学上海国际知识产权学院,上海200092 |
| |
| 基金项目： | 国家自然科学“制度演化影响下专利密集型产业知识溢出和区域创新联动机制研究”(71874122);国家自然科学“基于专利资产指数的专利组合价值评估与竞争策略研究”(71503081);中央高校基本科研业务费专项资金资助(22120180073)“基于收益分成模型和专利发展综合指数评价的医学科技创新成果转移转化新模式”. |
| |
| 摘 要： | 对江苏信息中心“新冠疫情专利信息平台”数据库中的专利分别进行整体结构、个体结构、药物维度和省市合作分析,发现:(1)我国防治新冠病毒化学药物专利合作网络规模、合作关系和合作次数一直在增加,但合作密度有所下降,该领域中各创新主体之间还存在着较大合作空间;(2)专利合作网络关键节点如大学、研究机构或企业等在不同阶段变动比较大,说明主体很难建立长期稳定的合作关系;(3)防治不同类型病毒的化学药物专利合作网络规模和网络密度演化情况有所不同,这与病毒的特性有关;(4)从我国省市合作中心来说,出现了以北京为核心逐步向长三角、珠三角的核心省市合作转移的情形.
|
| 关 键 词： | 新冠病毒 防治药物 专利合作 网络演化 |
| 收稿时间： | 2020/8/12 0:00:00 |
| 修稿时间： | 2020/8/30 0:00:00 |
Study on the Evolution of Patent Cooperation Network of Chemical Drugs for Prevention and Treatment of COVID-19 |
| |
| Jiang Nan,Liu Xing,Li Pengyuan.Study on the Evolution of Patent Cooperation Network of Chemical Drugs for Prevention and Treatment of COVID-19[J].Science and Technology Management Research,2021,41(7):140-147. |
| |
| Authors: | Jiang Nan Liu Xing Li Pengyuan |
| |
| Abstract: | The paper studied cooperative patent network of antiviral drugs for COVID-19 in China with the context of epidemic situation. It would enhance the cooperation of antiviral agents in China and expand the recognition of R D knowledge flow and innovation rules of Chinese antiviral agents. It studied the overall structure, individual structure, drug dimension and cooperation between provinces and cities, based on the database of "COVID-19 patent information platform" of Jiangsu information center. The main findings are as follows: (1) The scale, cooperation and cooperation frequency of COVID-19 related antiviral drug cooperation network have been increasing, but the density of cooperation has been decreasing. The trend shows that there is still a large space for cooperation among innovation subjects in this field; (2) Most of the key nodes such as universities, research institutions or enterprises, have great variation in patent cooperation network, which shows that there are difficulties to establish long-term and stable cooperation relationship among innovation subjects; (3) The patent cooperation network scale and network density of antiviral drugs have changed differently, which depends on the characteristics of the diseases; (4) From the perspective of cooperation center between provinces and cities in China, there is an evolving tendency from Beijing to the cooperation among the core provinces and cities in the Delta and the Pearl River Delta. |
| |
| Keywords: | COVID-19 Preventive and therapeutic drugs Patent Cooperation Network Evolution |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
| 点击此处可从《科技管理研究》浏览原始摘要信息 |
| 点击此处可从《科技管理研究》下载免费的PDF全文 |
|
